What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Enzyme
- Biochemistry
His main research concerns Pharmacology, Internal medicine, Endocrinology, Biochemistry and Mitochondrion.
The study incorporates disciplines such as CYP3A4 and Amiodarone in addition to Pharmacology.
His studies deal with areas such as Surgery, Pediatrics and HMG-CoA reductase as well as Internal medicine.
Stephan Krähenbühl has researched Endocrinology in several fields, including Transport protein and Glutathione.
In general Biochemistry study, his work on Coenzyme Q – cytochrome c reductase, Bile acid, Chenodeoxycholate and Ammonia often relates to the realm of N-Acetylglutamate synthase, thereby connecting several areas of interest.
His Mitochondrion research is multidisciplinary, incorporating elements of Oxidoreductase and Antioxidant.
His most cited work include:
- Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials (394 citations)
- Long-term metformin use is associated with decreased risk of breast cancer. (360 citations)
- Drug-related problems in hospitals: a review of the recent literature. (359 citations)
What are the main themes of his work throughout his whole career to date?
Stephan Krähenbühl mainly investigates Internal medicine, Pharmacology, Endocrinology, Mitochondrion and Pharmacokinetics.
The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Surgery.
As part of the same scientific family, he usually focuses on Pharmacology, concentrating on Toxicity and intersecting with Cytotoxicity.
His study connects Myopathy and Endocrinology.
His Mitochondrion research incorporates themes from Apoptosis and Reactive oxygen species.
The Pharmacokinetics study combines topics in areas such as Anesthesia and Bioavailability.
He most often published in these fields:
- Internal medicine (45.17%)
- Pharmacology (46.74%)
- Endocrinology (30.56%)
What were the highlights of his more recent work (between 2017-2021)?
- Pharmacology (46.74%)
- Internal medicine (45.17%)
- Pharmacokinetics (17.30%)
In recent papers he was focusing on the following fields of study:
Pharmacology, Internal medicine, Pharmacokinetics, Mitochondrion and Endocrinology are his primary areas of study.
His Pharmacology research integrates issues from CYP2D6, Cytochrome P450, Toxicity and In vivo.
His Internal medicine study frequently draws connections to adjacent fields such as Gastroenterology.
His biological study spans a wide range of topics, including Liquid chromatography–mass spectrometry and Drug.
His Mitochondrion research includes elements of Apoptosis, Reactive oxygen species, Neurotoxicity and SOD2.
His work in Apoptosis addresses issues such as Sunitinib, which are connected to fields such as Hepatocyte.
Between 2017 and 2021, his most popular works were:
- Mechanisms of statin-associated skeletal muscle-associated symptoms (28 citations)
- Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines. (21 citations)
- Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines. (21 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Enzyme
- Biochemistry
The scientist’s investigation covers issues in Pharmacology, Internal medicine, Mitochondrion, Endocrinology and Mitochondrial toxicity.
A large part of his Pharmacology studies is devoted to Pharmacokinetics.
His work carried out in the field of Internal medicine brings together such families of science as Protein kinase B, Oncology and mTORC2.
In his study, which falls under the umbrella issue of Mitochondrion, SOD2 and Oxidative stress is strongly linked to Reactive oxygen species.
His Endocrinology study often links to related topics such as Myopathy.
The Mitochondrial toxicity study which covers Ponatinib that intersects with Pazopanib.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
